Inhaled hypertonic saline in adults hospitalised for exacerbation of cystic fibrosis lung disease: A retrospective study

BMJ Open

Volumn 2, Issue 2, 2012, Pages

  Pezzulo, Alejandro A ^a   Stoltz, David A ^a   Hornick, Douglas B ^a   Durairaj, Lakshmi ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHLORIDE; TOBRAMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CYSTIC FIBROSIS; CYSTIC FIBROSIS LUNG DISEASE; CYTIC FIBROSIS LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; LUNG DISEASE; LUNG FUNCTION; MALE; PILOT STUDY; RETROSPECTIVE STUDY; SIDE EFFECT; SPUTUM CULTURE; WEIGHT GAIN;

EID: 84860907552     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000407     Document Type: Article

References (29)

1. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am J Dis Child 1938;56:344-99.
2. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001. (Pubitemid 40638370)
3. Döring G, Gulbins E. Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell Microbiol 2009;11:208-16.
4. Quinton PM. Physiological basis of cystic fibrosis: a historical perspective. Physiol Rev 1999;79:S3-22.
5. Goss CH, Burns JL. Exacerbations in cystic fibrosis: 1. Epidemiology and pathogenesis. Thorax 2007;62:360-7. (Pubitemid 46580580)
6. Bell SC, Robinson PJ. Exacerbations in cystic fibrosis: 2. Prevention. Thorax 2007;62:723-32.
7. Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3. Management. Thorax 2008;63:180-4.
8. Chang AB, Bilton D. Exacerbations in cystic fibrosis: 4. Non-cystic fibrosis bronchiectasis. Thorax 2008;63:269-76. (Pubitemid 351373725)
9. Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8.
10. Suri R, Grieve R, Normand C, et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax 2002;57:841-6. (Pubitemid 35178606)
11. Suri R, Marshall LJ, Wallis C, et al. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am J Respir Crit Care Med 2002;166:352-5. (Pubitemid 34864425)
12. Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358:1316-21. (Pubitemid 33016495)
13. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-50. (Pubitemid 43113029)
14. Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med 2006;12:445-52. (Pubitemid 44624606)
15. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40. (Pubitemid 43113028)
16. Ratjen F. Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. J Pediatr 2006;149:142.
17. Subbarao P, Balkovec S, Solomon M, et al. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 2007;42:471-6. (Pubitemid 46700947)
18. Taylor LM, Kuhn RJ. Hypertonic saline treatment of cystic fibrosis. Ann Pharmacother 2007;41:481-4. (Pubitemid 46536040)
19. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:627-32.
20. Eng PA, Morton J, Douglass JA, et al. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21:77-83. (Pubitemid 26098513)
21. Dmello D, Nayak RP, Matuschak GM. Stratified assessment of the role of inhaled hypertonic saline in reducing cystic fibrosis pulmonary exacerbations: a retrospective analysis. BMJ Open 2011;1: e000019.
22. Kuzik BA, Al-Qadhi SA, Kent S, et al. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediatr 2007;151:266e70, 270.e1.
23. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52:900-3. (Pubitemid 27473934)
24. Robinson M, Regnis JA, Bailey DL, et al. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996;153:1503-9. (Pubitemid 26141332)
25. Schoeffel RE, Anderson SD, Altounyan RE. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline. Br Med J (Clin Res Ed) 1981;283:1285-7. (Pubitemid 11026146)
26. Suri R, Metcalfe C, Wallis C, et al. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis. Pediatr Pulmonol 2004;37:305-10. (Pubitemid 38523942)
27. O'Byrne PM, Gauvreau GM, Brannan JD. Provoked models of asthma: what have we learnt? Clin Exp Allergy 2009; 39:181-92.
28. Frerichs C, Smyth A. Treatment strategies for cystic fibrosis: what's in the pipeline? Expert Opin Pharmacother 2009;10:1191-202.
29. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-69. (Pubitemid 350127838)